博雅生物(300294) - 2024年12月10日投资者关系活动记录表

Group 1: Business Outlook and Strategy - The blood products sector is a strategic focus for China Resources Pharmaceutical, with a commitment to enhancing the variety, quantity, and quality of blood products [2][4] - The company aims to align with national biological safety strategies and actively undertake tasks related to emerging industries [2][4] - The company has established a clear expansion plan for plasma stations, focusing on potential locations and strategies to enhance raw plasma supply capabilities [4] Group 2: Innovation and Product Development - The company is dedicated to R&D in blood products, with a product pipeline that includes human albumin, immunoglobulin, and coagulation factors [4] - The intravenous immunoglobulin (IVIG) product has received a supplementary application acceptance notice, while the von Willebrand factor (vWF) is in clinical trial stages [4] - The company emphasizes a combination of long-term and short-term R&D innovation strategies, integrating internal and external resources [4] Group 3: Corporate Governance and Financial Policies - China Resources Pharmaceutical has a robust risk compliance system and various management frameworks under its strategic control [2][4] - The company has a proactive and stable profit distribution policy, having implemented its first interim dividend since listing, aimed at increasing dividend frequency and ratio [4] - The company is open to mergers and acquisitions as part of its growth strategy, with a focus on blood products, while acknowledging the uncertainties involved [4]